|
Senetek PLC licensee granted exclusive agreement (SNTK) 0.62: Co announces that its lead Kinetin licensee, Valeant Pharma (VRX 18.14) has been granted the right to an exclusive worldwide license in all classes of trade for Senetek's patented cytokinin Zeatin, a naturally-occurring analogue of Kinetin. Under the agreement, Senetek is to begin pre-clinical testing of Zeatin, with expectations of completing pre-clinicals within four months for submission to the review board. Separately, Senetek announced an agreement with Valeant to make a $5 mln unrestricted cash payment to Senetek.
__________________
liebe Grüße von Coco
|